Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional collection · English
Collection mapEvidence & practical review

Stem Cells & Perinatal Therapies · Professional series · EN

The evidence desk: important findings through September 25, 2026

A dated, selective review of primary studies and official regulatory records—not an exhaustive systematic review.

By Olga Goodman, MD · Evidence through 25 September 2026

On this page
  1. How to read these cards
  2. August 2026 • Rheumatoid arthritis • Observational follow-up
  3. 2026 • Lupus nephritis • Retrospective, uncontrolled cohort
  4. 2026 • Aging-related frailty • Randomized phase 2b trial
  5. 2025 journal issue • Lupus • Phase I study
  6. 2025 • Systemic rheumatic disease • EBMT recommendations
  7. 2025 • Product development • Laboratory study
  8. 2023 • Knee osteoarthritis • MILES randomized trial
  9. 2019 • Knee osteoarthritis • Small randomized phase I/II trial
  10. 2016 • Chronic fatigue • Placebo-controlled extract study
  11. Regulatory milestones that must stay separate from trial results
  12. What this desk does not claim

How to read these cards

The labels below describe study design or regulatory status. They are not a validated evidence score and should not be collapsed into a single rating. A favorable safety signal, an efficacy result, and a product approval answer different questions. Publication date is separated from the period in which participants were treated where that distinction matters.

August 2026 • Rheumatoid arthritis • Observational follow-up

Park and colleagues followed nine participants from an early cord-blood-derived MSC study for five years. Early improvement in DAS28 diminished over time. Serious adverse events occurred in five patients; investigators did not attribute them to the infusion. One serious cellulitis event was reported, and there were no deaths, thromboembolic events, or malignancies in this small cohort. The data support longer-term observation, not definitive safety or durable efficacy. The authors’ suggestion to study repeated administration is a research question, not a treatment schedule. R10

2026 • Lupus nephritis • Retrospective, uncontrolled cohort

The Zheng report analyzed 120 patients receiving cord-derived MSCs alongside standard immunosuppression. The cumulative renal-response proportion at 12 months was 56.7%. Data came from 2009–2022; this was not a cohort first treated in 2026. There was no concurrent control group, and exclusions included insufficient follow-up and severe organ dysfunction. The findings are encouraging but cannot isolate the cell product’s effect, establish cure, or demonstrate superiority to standard treatment. R14

2026 • Aging-related frailty • Randomized phase 2b trial

The laromestrocel trial enrolled 155 adults aged 70–85 with selected frailty characteristics; 148 were infused and 143 entered the modified intention-to-treat analysis. It used allogeneic bone-marrow MSCs. For the highest-dose group versus placebo, the six-month walking-distance difference was 41.3 m (95% CI −2.4 to 84.9; p=.0635), not statistically significant. The nine-month comparison was favorable, and separate dose-response analyses were positive. These findings merit further study but are not a uniformly positive primary-outcome result or evidence of rejuvenation in healthy people. R19

2025 journal issue • Lupus • Phase I study

The Farge study, first published online in December 2024, treated eight patients with cord-derived MSCs. It was a single-center, open-label safety-oriented investigation. Its tolerability findings support further clinical development, not a conclusion that the approach is proven effective or equivalent to established lupus therapy. R13

2025 • Systemic rheumatic disease • EBMT recommendations

The EBMT publication addresses autologous hematopoietic transplantation as an integrated specialist program, with particular relevance to selected severe systemic sclerosis. It is a different evidence pathway from retail MSC infusions. Patient selection, experienced teams, and treatment-related risk remain central. R09

2025 • Product development • Laboratory study

Research on selected and pooled cord-MSC donors explored reduction of donor-dependent variability and immunomodulatory properties. The clinical implication is a quality question: how consistent is the final product? The study does not establish that a pooled commercial preparation produces better clinical outcomes. R21

2023 • Knee osteoarthritis • MILES randomized trial

MILES randomized 480 participants, with 440 in the primary analyses. BMAC, adipose SVF, and an allogeneic umbilical-tissue MSC product did not outperform corticosteroid injection on the primary pain outcomes at one year. MRI osteoarthritis scores did not improve. These findings challenge broad superiority and cartilage-regrowth claims for the tested approaches; they do not answer every possible product or future indication. R17

2019 • Knee osteoarthritis • Small randomized phase I/II trial

The Matas study enrolled 26 participants across hyaluronic-acid, single-MSC, and repeated-MSC groups. Some pain and function outcomes favored repeated administration of its specific cord-derived MSC product, but there were no MRI differences. The small sample and product-specific design limit generalization; the result does not establish a universal dosing regimen or cartilage restoration. R18

2016 • Chronic fatigue • Placebo-controlled extract study

The placental-extract study was a short trial of a biochemical preparation, not living cells. Its subgroup-dependent findings should not be repackaged as evidence for all fatigue, longevity, or MSC therapy. The dedicated chapter explains the formulation and population distinctions. R20

Regulatory milestones that must stay separate from trial results

RYONCIL: a genuine FDA-approved MSC product for a specific pediatric graft-versus-host-disease indication, not a general regenerative approval. MACI: a defined cultured-chondrocyte cartilage-repair product, not generic MSC treatment. LAVIV: an autologous-fibroblast regulatory precedent in a specific aesthetic indication; listing is not proof of current availability. Alofisel: its EU authorization was withdrawn in December 2024 and must not appear as a current authorization in a 2026 comparison. R02 R04 R03 R25 R26

What this desk does not claim

This is a clinician-oriented, curated review of selected primary publications and regulator records checked for this package. It is not a registered systematic review, a pooled estimate, a claim that every trial has been retrieved, or a live registry feed. “Current” means evidence checked through the stated date—not permanent completeness. New pivotal results, product changes, regulator actions, or major safety findings should trigger a targeted update.

Sources

R02. FDA. RYONCIL (remestemcel-L-rknd), product and approval information. Initial approval December 2024.

https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/ryoncil

Product-specific approval; pediatric steroid-refractory acute graft-versus-host disease. Access: Official FDA product page.

R03. FDA. LAVIV (azficel-T), product and indication information.

https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/laviv

Autologous fibroblasts; a regulatory example, not confirmation of current commercial availability. Access: Official FDA product page.

R04. FDA. MACI (autologous cultured chondrocytes on porcine collagen membrane), product and indication information.

https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/maci-autologous-cultured-chondrocytes-porcine-collagen-membrane

Product-specific cartilage repair; not a stem-cell injection for generalized osteoarthritis. Access: Official FDA product page.

R09. Alexander T, et al. Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee. Bone Marrow Transplant. 2025;60:1451–1464. doi:10.1038/s41409-025-02695-y.

https://www.nature.com/articles/s41409-025-02695-y

Published August 20, 2025. Center selection and multidisciplinary recommendations; underlying literature search through September 2024. Access: Publisher full text.

R10. Park EH, et al. Long-term safety of intravenous human umbilical cord blood-derived mesenchymal stem cell therapy in rheumatoid arthritis: a 5-year follow-up study. Stem Cells Transl Med. 2026;15(8):szag062. doi:10.1093/stcltm/szag062.

https://academic.oup.com/stcltm/article/15/8/szag062/8752872

Published August 5, 2026. Nine-patient observational follow-up; full results read, not just the optimistic significance statement. Access: Publisher full text.

R13. Farge D, et al. Allogeneic umbilical cord-derived mesenchymal stromal cells as treatment for systemic lupus erythematosus: a single-centre, open-label, dose-escalation, phase 1 study. Lancet Rheumatol. 2025;7:e261–e273. doi:10.1016/S2665-9913(24)00298-4.

https://pubmed.ncbi.nlm.nih.gov/39706212/

Online December 17, 2024; April 2025 issue. Abstract checked; eight treated patients. Access: PubMed abstract.

R14. Zheng Y, et al. Allogeneic umbilical cord-derived mesenchymal stromal cells for treatment of refractory lupus nephritis: a real-world study. Stem Cell Res Ther. 2026;17:201. doi:10.1186/s13287-026-05021-5.

https://link.springer.com/article/10.1186/s13287-026-05021-5

Published April 18, 2026; version of record June 1, 2026. Retrospective data from 2009–2022; uncontrolled. Access: Publisher full text.

R17. Mautner K, et al. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med. 2023;29:3120–3126. doi:10.1038/s41591-023-02632-w.

https://www.nature.com/articles/s41591-023-02632-w

MILES trial. 480 randomized, 440 in primary analyses. Associated correction: doi:10.1038/s41591-023-02776-9. Access: Publisher full text.

R18. Matas J, et al. Umbilical Cord-Derived Mesenchymal Stromal Cells for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial. Stem Cells Transl Med. 2019;8:215–224. doi:10.1002/sctm.18-0053.

https://pubmed.ncbi.nlm.nih.gov/30592390/

Small 26-patient study; symptom findings do not establish cartilage regrowth. Access: PubMed abstract.

R19. Ruiz JG, et al. Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty. Cell Stem Cell. 2026;33:393–404.e4. doi:10.1016/j.stem.2026.01.017.

https://pmc.ncbi.nlm.nih.gov/articles/PMC13035327/

Online February 25, 2026; March 5, 2026 issue. Primary comparison and later/dose-response analyses must be distinguished. Access: PMC full text.

R20. Park SB, et al. Human Placental Extract as a Subcutaneous Injection Is Effective in Chronic Fatigue Syndrome: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study. Biol Pharm Bull. 2016;39:674–679. doi:10.1248/bpb.b15-00623.

https://www.jstage.jst.go.jp/article/bpb/39/5/39_b15-00623/_html/-char/en

Extract, not live cells. Short-term subgroup findings; title must not be treated as a universal clinical conclusion. Access: Publisher full text.

R21. Mebarki M, et al. Pooling umbilical cord-mesenchymal stromal cells derived from selected multiple donors reduces donor-dependent variability and improves their immunomodulatory properties. Stem Cell Res Ther. 2025;16:252. doi:10.1186/s13287-025-04361-y.

https://pubmed.ncbi.nlm.nih.gov/40394664/

Laboratory/manufacturing study; not proof of better clinical outcomes from donor pooling. Access: PubMed abstract.

R25. European Medicines Agency. Alofisel withdrawn from the EU market. December 2024.

https://www.ema.europa.eu/en/news/alofisel-withdrawn-eu-market

A product-specific example of reassessment after confirmatory evidence. Access: Official regulator notice information.

R26. European Medicines Agency. Alofisel (darvadstrocel): European Public Assessment Report and withdrawal status.

https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel

Authorization withdrawn December 13, 2024; do not present as a currently authorized EU product. Access: Official regulator status information.

Olga Goodman, MD · Rheumatology in Perspective · A RheumaView publication

Educational publication; not individualized medical advice or procedure clearance. No dosing protocol is provided. This is a selective, dated review rather than an exhaustive systematic review.

Original text requires author and source attribution. Do not submit personal medical information in public comments.

Back to top

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: 2026 evidenceClinical trialsfrailtylupus nephritisRAregulatory update